Bristol Myers to sell 60% stake in China joint venture

Core Viewpoint - U.S. drugmaker Bristol Myers Squibb has signed an agreement to sell its 60% ownership stake in a pharmaceutical joint venture in China [1] Company Summary - Bristol Myers Squibb is divesting its majority stake in a joint venture, indicating a strategic shift in its operations in the Chinese market [1] Industry Summary - The sale reflects ongoing trends in the pharmaceutical industry where companies are reassessing their international partnerships and market presence, particularly in rapidly evolving markets like China [1]